First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial
Filed with ASX · · 6 pages · English
Earlier from Ceretas
- Notice of Annual General Meeting/Proxy Form
- Investor Presentation - October 2026
- Date of AGM and Closing Date for Director Nominations
- Milestone 3 Completed for CUREator Program
- Ethics Committee Approval Secured for Additional Trial Sites
Later from Ceretas
All Ceretas news releasesFollow Ceretas into a list and get an email when it puts out news.
Follow Ceretas